Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18145804 | 1.00 | FOLH1 (0.60) | FOLH1LMNA | |
| SCHEMBL29798933 | 0.95 | FOLH1 (0.65) | FOLH1LMNA | |
| SCHEMBL14719860 | 0.86 | FOLH1 (0.57) | FOLH1 | |
| SCHEMBL14719862 | 0.86 | FOLH1 (0.57) | FOLH1 | |
| SCHEMBL18145530 | 0.85 | ALDH1A1 (0.57) | — | |
| SCHEMBL14729380 | 0.85 | ALDH1A1 (0.57) | — | |
| SCHEMBL14719940 | 0.84 | FOLH1 (0.48) | FOLH1 | |
| SCHEMBL14720022 | 0.84 | FOLH1 (0.48) | FOLH1 | |
| SCHEMBL4919361 | 0.83 | NAALAD2 (0.61) | FOLH1LMNA | |
| SCHEMBL4919365 | 0.83 | NAALAD2 (0.61) | FOLH1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583887-B2 | PSMA imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12559521-B2 | PSMA imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20240425547-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2024-12-26 | — | — | US | disclosed |
| US-20240409580-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2024-12-12 | — | — | US | disclosed |
| US-12139554-B2 | PSMA imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-12122851-B2 | PSMA imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| US-20210032286-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2021-02-04 | — | — | US | disclosed |
| US-20210032286-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2021-02-04 | — | — | US | disclosed |
| US-20210024574-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2021-01-28 | — | — | US | disclosed |
| US-20210024574-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2021-01-28 | — | — | US | disclosed |
| US-20200377549-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200377549-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20180258134-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2018-09-13 | — | — | US | disclosed |
| US-10011632-B2 | PSMA imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011632-B2 | PSMA imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011632-B2 | PSMA imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20160304555-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160304555-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160304555-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2016-10-20 | — | — | US | disclosed |
| WO-2013028664-A1 | PSMA IMAGING AGENTS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425547-A1 | PSMA Imaging Agents | FOLH1, KLK3, PSMA2 | FOLH1 1/4885LMNA 3855/4885 |
| US-20180258134-A1 | PSMA Imaging Agents | FOLH1, KLK3, PSMA2 | FOLH1 1/4885LMNA 3855/4885 |
| US-20240409580-A1 | PSMA Imaging Agents | FOLH1, KLK3, PSMA2 | FOLH1 1/4885LMNA 3855/4885 |
| US-12559521-B2 | PSMA imaging agents | KLK3, PSMA1, PSMA6 | FOLH1 4/4885LMNA 2537/4885 |
| US-12139554-B2 | PSMA imaging agents | FOLH1, KLK3, PSMA2 | FOLH1 1/4885LMNA 3855/4885 |
| US-20200377549-A1 | PSMA Imaging Agents | FOLH1, KLK3, PSMA2 | FOLH1 1/4885LMNA 3855/4885 |
| US-12583887-B2 | PSMA imaging agents | KLK3, PSMA3, PSMA1 | FOLH1 4/4885LMNA 2254/4885 |
| US-20210032286-A1 | PSMA Imaging Agents | FOLH1, KLK3, PSMA2 | FOLH1 1/4885LMNA 3855/4885 |
| US-10011632-B2 | PSMA imaging agents | FOLH1, KLK3, PSMA2 | FOLH1 1/4885LMNA 3855/4885 |
| US-12122851-B2 | PSMA imaging agents | FOLH1, KLK3, PSMA2 | FOLH1 1/4885LMNA 3855/4885 |
| US-20210024574-A1 | PSMA Imaging Agents | FOLH1, KLK3, PSMA2 | FOLH1 1/4885LMNA 3855/4885 |
| US-20160304555-A1 | PSMA Imaging Agents | FOLH1, KLK3, PSMA2 | FOLH1 1/4885LMNA 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.